[Recent developments in chemotherapy of malignant diseases].
D000880:Anthraquinones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000145:classification; D000971:Antineoplastic Combined Chemotherapy Protocols; D001932:Brain Neoplasms / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy; D002945:Cisplatin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D005821:Genetic Techniques; D006689:Hodgkin Disease / Q000188:drug therapy; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008942:Mitoxantrone; D009362:Neoplasm Metastasis / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy*; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D012516:Osteosarcoma / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000032:analysis; D014212:Tretinoin / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000880:Anthraquinones; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D006728:Hormones; D009607:Nitrosourea Compounds; D011956:Receptors, Cell Surface; D011344:Procarbazine; D008466:Mechlorethamine; D014212:Tretinoin; D014750:Vincristine; D007372:Interferons; D008942:Mitoxantrone; D002945:Cisplatin; D011241:Prednisone; D008727:Methotrexate
Neuere Entwicklungen in der Chemotherapie maligner Erkrankungen.